Users new to the Omnipod 5 AID System can complete training and onboarding via personalized trainer-led education, virtually or in-person, or for those upgrading from an earlier Omnipod System, online, self-guided training modules can be completed. This study aimed to evaluate outcomes by training type among people with T1D initiating the Omnipod 5 System. Continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users in the US with T1D aged ≥2y and using ≥5 units of insulin per day with ≥90 days of data available in the cloud-based data management system were included. Data from 31,027 users with sufficient CGM data (≥75% of days with ≥220 readings) and using the lowest target setting (average glucose target of 110mg/dL) aged <18y (n=6,774) and ≥18y (n=24,253) were available at the time of analysis. For pediatric users, 35.9% completed self-guided training and 64.1% completed trainer-led education (20.4% in-person; 43.7% virtual). In adults, trainer-led education was more common (75.1% of users: 24.6% in-person; 50.5% virtual). Glycemic outcomes and percent time in Automated Mode were similar across training types (Table). These findings from over 31,000 people using the Omnipod 5 AID System support the effectiveness of virtual and self-guided training for AID systems and support expansion of these options to facilitate convenient and timely access to AID technology.

graphic
View largeDownload slide
Disclosure

C. Berget: Speaker's Bureau; Dexcom, Inc., Insulet Corporation, embecta. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. D. DeSalvo: Advisory Panel; Insulet Corporation. Consultant; Dexcom, Inc. G. Aleppo: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Consultant; Medscape. Research Support; MannKind Corporation, Tandem Diabetes Care, Inc., WellDoc, Fractyl Health, Inc. Consultant; Eli Lilly and Company, Bayer Inc. Research Support; Emmes. E.G. Wilmot: Other Relationship; Abbott. Speaker's Bureau; AstraZeneca. Other Relationship; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, embecta, Medtronic, Novo Nordisk. Advisory Panel; Roche Diabetes Care. Other Relationship; Sanofi. Speaker's Bureau; Ypsomed AG. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. I. Hadjiyianni: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. J.J. Mendez: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. L. Conroy: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. T.T. Ly: Employee; Insulet Corporation.

Funding

Insulet Corporation

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.